All In Biotech

Drug Trial Radar · NCT00374777

A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients

FK199B (Zolpidem MR Tablet) Phase III Clinical Study -A Double-Blind, Placebo- and Nitrazepam-Controlled, Group-Comparison Study in Patients With Insomnia Associated With Schizophrenia and Manic-Depressive Psychosis

Last checked: Nov 19, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

450

Actual

Start

Aug 2006

Primary completion

May 2008

Study completion Jun 2008

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Sep 11, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, triple-dummy, group-comparison study using placebo and nitrazepam as a comparative drug.

Conditions

  • Sleep Initiation and Maintenance Disorders

Interventions

  • zolpidem MRDrug

    oral

  • nitrazepamDrug

    oral

  • placeboDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean wake time after sleep onset during the double-blind periodTime frame: 2 Weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chubu Region, Japan

  • Site not named

    Hokkaido Region, Japan

  • Site not named

    Kansai Region, Japan

  • Site not named

    Kanto Region, Japan

  • Site not named

    Kyushu Region, Japan

  • Site not named

    Shikoku Region, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.